Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]
Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD)
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
galmedpharma.investorroom.com
Company Research
Source: TheStreet.com
advancement in its clinical development pipeline . The company is successfully developing a new, brain-penetrating formulation of its lead candidate, Aramchol. This breakthrough marks a strategic pivot from purely metabolic liver research into the high-value central nervous system (CNS) market. Analysts suggest this move could dramatically increase the firm's total addressable market. The new formulation is designed to cross the blood-brain barrier with high efficiency. The Technical Mechanism of CNS Penetration Aramchol functions primarily as a Stearoyl-CoA Desaturase 1 (SCD1) inhibitor. Specifically, this enzyme plays a critical role in lipid metabolism and cellular stress responses. The original formulation was designed to target metabolic-associated steatohepatitis (MASH). Furthermore, the newer variant utilizes a proprietary delivery system to bypass neurological defenses. This allows the active pharmaceutical ingredient to reach neural tissues directly. In light of this deve
Show less
Read more
Impact Snapshot
Event Time:
GLMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLMD alerts
High impacting Galmed Pharmaceuticals Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GLMD
News
- Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain CancersPR Newswire
- Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholPR Newswire
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]TheStreet.com
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025PR Newswire
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationPR Newswire
GLMD
Sec Filings
- 4/14/26 - Form 6-K
- 4/9/26 - Form 6-K
- 4/2/26 - Form EFFECT
- GLMD's page on the SEC website